2014 in review – new medicines listed in the New Zealand Pharmaceutical Schedule
Michael Wonder - January 2015
www.maestrodatabase.com
2014 saw the listing of 14 new medicines in the New Zealand
Pharmaceutical Scheme. These new listings are summarised below. All bar of these 14 new listings are listed
in the Schedule of Pharmaceutical Benefits Schedule in Australia; most were
listed several years ago.
New medicines listed in the New Zealand
Pharmaceutical Schedule in 2014
Month
|
Medicine
|
Disease/condition
|
Sponsor
|
Date of listing in the
Schedule of Pharmaceutical Benefits Schedule (Australia)
|
January
|
Eltrombopag olamine (Revolade)
|
Idiopathic
thrombocytopaenic purpura
|
GSK
|
1/11/2011
|
February
|
Nil
|
|||
March
|
Nil
|
|||
April
|
Nil
|
|||
May
|
Nil
|
|||
June
|
Febuxostat (Adenuric)
|
Gout
|
Te Arai Biofarma
|
Not listed
|
July
|
Nil
|
|||
August
|
Rifaximin (Xifaxan)
|
Hepatic
encephalopathy
|
Norgine
|
1/12/2013
|
September
|
Azacitidine (Vidaza)
|
Myelodysplastic syndromes
|
Celgene
|
1/02/2011
|
Lenalidomide (Revlimid)
|
Multiple myeloma
|
Celgene
|
1/11/2009
|
|
October
|
Nil
|
|||
November
|
Tobramycin (Tobi)
|
Bacterial infection
|
Novartis
|
1/04/2014
|
Fingolimod hydrochloride (Gilenya)
|
Multiple sclerosis
|
Novartis
|
1/09/2011
|
|
Natalizumab (Tysabri)
|
Multiple sclerosis
|
Biogen Idec
|
1/07/2008
|
|
Rivastigmine (Exelon)
|
Alzheimer’s disease
|
Novartis
|
1/07/2008
|
|
Nilotinib hydrochloride monohydrate
(Tasigna)
|
Chronic myeloid leukaemia
|
Novartis
|
1/08/2008
|
|
Glycopyrronium bromide (Seebri
Breezhaler)
|
Chronic obstructive pulmonary disease
|
Novartis
|
1/04/2014
|
|
Indacaterol maleate (Onbrez)
|
Chronic obstructive pulmonary disease
|
Novartis
|
1/12/2011
|
|
Deferasirox (Exjade)
|
Iron overload
|
Novartis
|
1/12/2006
|
|
Everolimus (Afinitor)
|
Tuberous
sclerosis complex
|
Novartis
|
1/12/2013
|
|
December
|
Nil
|
©
Wonder Drug Consulting Pty Ltd, 2015.
